Effects of Fluvoxamine and Paroxetine on Sleep Structu

Journal of Clinical Psychiatry 62, 642-652

DOI: 10.4088/jcp.v62n0812

Citation Report

#	Article	IF	CITATIONS
1	SSRI Treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. Journal of Sleep Research, 2001, 10, 129-142.	1.7	74
3	Management of Insomnia in Patients With Chronic Obstructive Pulmonary Disease. Drugs, 2003, 63, 379-387.	4.9	68
4	Consensus on Drug Treatment, Definition and Diagnosis for Insomnia. Clinical Drug Investigation, 2003, 23, 351-385.	1.1	44
5	Cluster Headache Patients Show Marked Intensity Dependence of Cortical Auditory Evoked Potentials during and outside the Bout. Cephalalgia, 2005, 25, 36-40.	1.8	17
6	Antidepressants and their effect on sleep. Human Psychopharmacology, 2005, 20, 533-559.	0.7	260
7	Sleep quality deteriorates over a binge–abstinence cycle in chronic smoked cocaine users. Psychopharmacology, 2005, 179, 873-883.	1.5	71
8	Drugs That Disturb Sleep and Wakefulness. , 2005, , 499-518.		13
9	Fluoxetine during pregnancy: impact on fetal development. Reproduction, Fertility and Development, 2005, 17, 641.	0.1	76
10	Tolerability and safety of fluvoxamine and other antidepressants. International Journal of Clinical Practice, 2006, 60, 482-491.	0.8	71
11	Medications and Sleep in Nursing Home Residents With Dementia. Journal of the American Psychiatric Nurses Association, 2006, 12, 279-285.	0.4	7
13	Sleep onset REM periods in obsessive compulsive disorder. Psychiatry Research, 2007, 152, 29-35.	1.7	46
14	Depression and poor sleep: The effect of monoaminergic antidepressants in a pre-clinical model in rats. Pharmacology Biochemistry and Behavior, 2007, 86, 468-476.	1.3	28
15	Failure to Find Executive Function Deficits Following One Night's Total Sleep Deprivation in University Students Under Naturalistic Conditions. Behavioral Sleep Medicine, 2009, 7, 136-163.	1.1	31
16	Review: Problems associated with long-term treatment with selective serotonin reuptake inhibitors. Journal of Psychopharmacology, 2009, 23, 967-974.	2.0	112
17	The electrophysiology of cluster headache. Current Pain and Headache Reports, 2009, 13, 155-159.	1.3	9
18	Differences in clinical effect and tolerance between fluvoxamine and paroxetine: A switching study in patients with depression. Human Psychopharmacology, 2010, 25, 525-529.	0.7	O
19	Multiple sleep latency test: Are the practice and interpretation of the test valid?. Sleep Medicine, 2013, 14, 127-128.	0.8	3
20	Extreme REM Rebound during Continuous Positive Airway Pressure Titration for Obstructive Sleep Apnea in a Depressed Patient. Case Reports in Medicine, 2014, 2014, 1-4.	0.3	4

#	Article	IF	Citations
21	Sleep enhances exposure therapy. Psychological Medicine, 2014, 44, 1511-1519.	2.7	114
22	Decreased delta sleep ratio and elevated alpha power predict vulnerability to depression during interferon-alpha treatment. Acta Neuropsychiatrica, 2015, 27, 14-24.	1.0	12
23	Translational neurophysiological markers for activity of the metabotropic glutamate receptor (mGluR2) modulator JNJ-40411813: Sleep EEG correlates in rodents and healthy men. Neuropharmacology, 2016, 103, 290-305.	2.0	11
24	Characteristics of objective daytime sleep among individuals with earthquake-related posttraumatic stress disorder: A pilot community-based polysomnographic and multiple sleep latency test study. Psychiatry Research, 2017, 247, 43-50.	1.7	9
25	The Effect Of Fluvoxamine On Sleep Architecture Of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study. Nature and Science of Sleep, 2019, Volume 11, 291-300.	1.4	10
26	REM sleep-dependent short-term and long-term hourglass processes in the ultradian organization and recovery of REM sleep in the rat. Sleep, 2020, 43, .	0.6	7
27	Postoperative analgesia using dezocine alleviates depressive symptoms after colorectal cancer surgery: A randomized, controlled, double-blind trial. PLoS ONE, 2020, 15, e0233412.	1.1	16
28	Serotonin and dreaming., 2008,, 307-324.		4
29	Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson's disease. Neurology, 2004, 63, S35-8.	1.5	55
30	mGlu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary Efficacy on Sleep Measures in Rats. PLoS ONE, 2015, 10, e0144017.	1.1	16
31	Eszopiclone Treatment for Insomnia. primary care companion for CNS disorders, The, 2012, 14, .	0.2	13
32	Pregabalin reduces sleep disturbance in patients with generalized anxiety disorder via both direct and indirect mechanisms. European Journal of Psychiatry, 2010, 24, .	0.7	14
33	An Unexpected Polysomnogram Finding. Journal of Clinical Sleep Medicine, 2016, 12, 1567-1569.	1.4	1
34	Advance taper of antidepressants prior to multiple sleep latency testing increases the number of sleep-onset rapid eye movement periods and reduces mean sleep latency. Journal of Clinical Sleep Medicine, 2020, 16, 1921-1927.	1.4	7
35	Sleep in Children with Psychiatric and Behavioral Problems. , 2017, , 389-404.		1
36	Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatric Disease and Treatment, 2005, 1 , 289-99.	1.0	33